TacticScaleWhat WuXi Biologics Does & How It Makes Money (2269.HK)
Updated October 2026 · reflects WuXi Biologics's latest reported financials
Contract research, development and manufacturing partner for biologic drugs. It earns service fees from biopharma clients who outsource biologic discovery, development, testing and manufacturing to its CRDMO platforms.
How WuXi Biologics makes money
It earns service fees from biopharma clients who outsource biologic discovery, development, testing and manufacturing to its CRDMO platforms. Revenue comes from two segments, Biologics and XDC.
What WuXi Biologics does
WuXi Biologics (Cayman) Inc. is a contract research, development and manufacturing organization (CRDMO) for biologic drugs. Its services cover the whole process, from discovery and IND filing through CMC, process development, testing and clinical and commercial manufacturing. It reports two segments, Biologics and XDC, and also runs a vaccine CDMO business. The company has its own technology platforms, including WuXiBody, SDArBodY, T cell engager, TAA mAb, Single B Cell Cloning, WuXia, WuXiUP, WuXiUI and WuXiHigh. It serves customers in China, North America, Europe, Singapore, Japan, South Korea, Australia and Brazil. It was incorporated in 2014 and is headquartered in Wuxi, China.
Products & services
- End-to-end biologics CRDMO services
- WuXiBody bispecific antibody platform
- SDArBodY and T cell engager technologies
- WuXia, WuXiUP, WuXiUI and WuXiHigh platforms
- XDC (drug conjugate) development and manufacturing
- Vaccine CDMO services
What is WuXi Biologics worth?
On an owner-earnings DCF, WuXi Biologics's most-likely value is about HK$21 versus a recent price near HK$53 (148% above fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~HK$6) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
⚠ Capital-intensive — this business reinvests heavily, so free cash flow runs well below its earnings. Fair value here is built on free cash flow, which understates owner earnings for reinvestment-heavy companies — read it as conservative.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
WuXi AppTec (603259.SS) · Bio-Thera Solutions (688177.SS) · Hybio Pharmaceutical (300199.SZ)